Market Access News | pharmaphorum

News

Home testing devices for sleep apnoea backed for NHS use

Five home-testing devices for obstructive sleep apnoea hypopnoea syndrome (OSAHS), a potentially dangerous condition affecting 2.5 million adults in the UK, have been reco

News

Eisai, Biogen start delayed subcutaneous Leqembi filing

Eisai and Biogen have filed a rolling biologics license application in the US for a subcutaneous formulation of Alzheimer’s disease therapy Leqembi that was delayed by the

News

FDA clears Roche self-collection system for HPV screening

The US FDA has approved a human papillomavirus (HPV) self-sampling solution developed by Roche that allows patients to collect a sample themselves in a healthcare setting.

News

ICER raps conduct of Lykos’ psychedelic trial for PTSD

The Institute for Clinical and Economic Review (ICER) typically focuses on the cost-effectiveness of new therapies, but in an unusual move has sharply criticised the desig

News

FDA delays decision on Moderna’s RSV vaccine

Moderna’s first attempt to expand its commercial activities beyond COVID-19 vaccines, its respiratory syncytial virus (RSV) shot, has suffered a delay in the US.

News

Pfizer reaches deal with NICE on Vyndaqel for ATTR-CM

Three years after turning it down for being too expensive, NICE has backed the use of Pfizer’s Vyndaqel as a treatment for transthyretin amyloidosis with cardiomyopathy (A

Home testing devices for sleep apnoea backed for NHS use

Eisai, Biogen start delayed subcutaneous Leqembi filing

FDA clears Roche self-collection system for HPV screening

ICER raps conduct of Lykos’ psychedelic trial for PTSD

FDA delays decision on Moderna’s RSV vaccine

Pfizer reaches deal with NICE on Vyndaqel for ATTR-CM

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks